Top Pot Stocks for the Next Generation of Cannabis Products

Hexo Corp (TSX:HEXO)(NYSE:HEXO) and Canopy Growth Corp (TSX:WEED)(NYSE:CGC) are your top choices for the cannabis future.

| More on:
edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

It’s time for a new chapter in pot investing.

In 2018, cannabis stocks soared as the market rushed to take advantage. Last year, the tides turned, as valuations came down from nosebleed levels. In 2020, the story will evolve again, even if few investors are prepared.

The biggest shift will be a newfound appreciation for novel cannabis form factors. In previous bull runs, capital was infatuated with conventional pot production, which mostly included dry flowers. The next bull run will be fueled by value-add products like beverages, edibles, vapes, medicines, and more.

Many cannabis stocks are not ready to take advantage of this emerging opportunity. In fact, most are still focused on ramping raw cannabis production — a strategy that will experience heavy pricing pressure this year.

Value-add pot products could ultimately double or even triple the value of the global cannabis market. Want to get direct exposure before other investors come flooding in? The following picks are your best bets.

The road less traveled

Read up on nearly any pot stock, and you’ll find the same strategy: ramp cannabis production as quickly as possible and then roll out new brands to woo customers. You should be very leery of this model.

First, while it’s a bit different than tomatoes, cannabis is still just a crop. It’s not terribly difficult to grow. Yield rates and economies of scale can be tinkered with, but, despite what most companies claim, there will be a race to the bottom for pricing. This is what happens when every company believes that they can grow more cheaply than the competition.

Hexo (TSX:HEXO)(NYSE:HEXO) is avoiding the hassle of building its own brands to preserve pricing power. Instead, it’s outsourcing the entire process to existing brands that consumers already know and love. Its partnership with Molson Coors Canada is a perfect example.

Molson sold more than $2 billion in beer last year to Canadian consumers, giving it the largest market share in the country by far. It’s fair to say that Canadians love Molson. That’s why Hexo co-developed a cannabis-infused beverage directly with Molson. With pre-established trust and loyalty, these products should take the market by storm.

The Hexo-Molson products will hit shelves this month. It’s an ideal situation for both companies. Hexo can leverage Molson’s brand power, while Molson can outsource all of its cannabis production and processing. In 2020, expect Hexo to gain sales traction and attract new partners for other value-add cannabis verticals.

Playing the long game

Canopy Growth took a similar route to Hexo, tying itself to one of the largest alcohol distributors in North America: Constellation Brands. With powerful brands like Corona, Robert Mondavi, and Modelo, Constellation has a proven track record of turning commoditized ingredients into high-margin consumer products.

With its cash hoard and powerful partner, Canopy should ultimately release value-add products across multiple categories. Its facility in Smiths Falls is producing cannabis-infused chocolates, with additional products planned. It’s developed a proprietary process that distills whole-flower cannabis into a clear liquid for beverage manufacturing. And it has already designed a line of vape pens and vape cartridges.

Due to R&D requirements, it will take more time to get value-add products to market, but when pricing power is affirmed, expect analysts and institutional investors to flock to these names.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends Constellation Brands, HEXO., and HEXO. Fool contributor Ryan Vanzo has no position in any stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »